97 research outputs found
Estudio experimental y numérico del comportamiento de un modelo de difusor de aire por desplazamiento acoplado a un suelo frío
En la última década se han realizado muchos trabajos sobre sistemas de refrigeración para grandes superficies usando ventilación por desplazamiento con suelos radiantes (por ejemplo en aeropuertos y estaciones). De especial interés tiene el conocimiento de los campos de velocidad y de temperatura.
De forma simplificada, en este estudio se presentan los resultados de un difusor a escala que utiliza ventilación por desplazamiento con suelo radiante frío. Tres son los parámetros que se modifican: el caudal (Q), la diferencia entre la temperatura ambiente y el aire de impulsión (dT1) y la diferencia entre la temperatura del suelo y el aire de impulsión (dT2).
Las visualizaciones y mediciones del campo de velocidad del flujo se han realizado para un régimen laminar en estado estacionario. Además, las simulaciones numéricas del campo de temperatura representado en la figura muestran buena concordancia con los datos experimentales.
Las zonas de mayor interés en este estudio son: la salida del difusor, la zona cercana al suelo y la zona lejos del difusor sobre el suelo, donde las condiciones de contorno se discuten con detalle.
La distancia radial (r) para la que cada difusor afecta a su alrededor en los términos de gradiente de temperatura y de velocidad es un parámetro importante para el diseño de la distribución espacial de estos difusores. Los principales resultados de este trabajo se basan en la relación r = f (Q, dT1, dT2).AIRZON
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
Background: The aim of this study was to analyze the impact of the presence of heart failure (HF) on
the clinical profile and outcomes in patients with atrial fibrillation (AF) anticoagulated with rivaroxaban.
Methods: Observational and non-interventional study that included AF adults recruited from 79
Spanish centers, anticoagulated with rivaroxaban ≥ 6 months before inclusion. Data were analyzed
according to baseline HF status.
Results: Out of 1,433 patients, 326 (22.7%) had HF at baseline. Compared to patients without HF, HF
patients were older (75.3 ± 9.9 vs. 73.8 ± 9.6 years; p = 0.01), had more diabetes (36.5% vs. 24.3%;
p < 0.01), coronary artery disease (28.2% vs. 12.9%; p < 0.01), renal insufficiency (31.7% vs. 22.6%; p = 0.01), higher CHA2DS2-VASc (4.5 ± 1.6 vs. 3.2 ± 1.4; p < 0.01) and HAS-BLED (1.8 ± 1.1 vs.
1.5 ± 1.0; p < 0.01). After a median follow-up of 2.5 years, among HF patients, annual rates of stroke/
/systemic embolism/transient ischemic attack, major adverse cardiovascular events (MACE) (non-fatal
myocardial infarction, revascularization and cardiovascular death), cardiovascular death, and major
bleeding were 1.2%, 3.0%, 2.0%, and 1.4%, respectively. Compared to those patients without HF, HF patients had greater annual rates of MACE (3.0% vs. 0.5%; p < 0.01) and cardiovascular death (2.0% vs.
0.2%; p < 0.01), without significant differences regarding other outcomes, including thromboembolic or
bleeding events. Previous HF was an independent predictor of MACE (odds ratio 3.4; 95% confidence
interval 1.6–7.3; p = 0.002) but not for thromboembolic events or major bleeding.
Conclusions: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical
profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with
the development of MACE, but not with thromboembolic events or major bleeding. (Cardiol J 2022; 29,
6: 936–947)
Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study
atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE.
Methods: This was a post-authorization and observational study of AF adults treated with rivaroxaban for
≥ 6 months. The primary endpoint was any of the major adverse cardiac events (MACE), namely, cardiovas cular death, non-fatal myocardial infarction, and myocardial revascularization. The area under the curve
(AUC) was calculated to evaluate the performance of 2MACE, and a new score, 2MACER to predict MACE.
Results: A total of 1433 patients were included (74.2 ± 9.7 years, CHA2DS2-VASc 3.5 ± 1.5, 26.9%
2MACE ≥ 3). The annual event rates (follow-up 2.5 years) were 1.07% for MACE, 0.66% for throm boembolic events and 1.04% for major bleeding. Patients with 2MACE ≥ 3 (vs. < 3) had higher risk
of stroke/systemic embolism/transient ischemic attack (odds ratio [OR] 5.270; 95% confidence interval
[CI] 2.216–12.532), major bleeding (OR 4.624; 95% CI 2.163–9.882), MACE (OR 3.202; 95% CI
1.548–6.626) and cardiovascular death (OR 3.395; 95% CI 1.396–8.259). 2MACE was recalcu lated giving 1 more point to patients with baseline a glomerular filtration rate < 50 mL/min/1.73 m2
(2MACER); (2MACER vs. 2MACE: IDI 0.1%, p = 0.126; NRI 23.9%, p = 0.125; AUC: 0.651 [95%
CI 0.547–0.755] vs. 0.638 [95% CI 0.534–0.742], respectively; p = 0.361).
Conclusions: In clinical practice, AF patients anticoagulated with rivaroxaban exhibit a low risk of events.
2MACE score acts as a modest predictor of a higher risk of adverse outcomes in this population. 2MACER
did not significantly increase the ability of 2MACE to predict MACE. (Cardiol J 2022; 29, 4: 601–609
Right Ventricular Function in long-term survivors of childhood acute Lymphoblastic Leukemia: from the CTOXALL study
There are limited data regarding right ventricle (RV) impairment in long-term survivors of childhood acute lymphoblastic leukemia (CLS). The aim of this study was to assess RV function in these patients using echocardiographic conventional measurements and automated RV strain. Echocardiographic recordings of 90 CLS and 58 healthy siblings from the CTOXALL cohort were analyzed. For group comparisons, inverse probability weighting was used to reduce confounding. The CLS group (24.6 ± 9.7 years, 37.8% women) underwent an echocardiographic evaluation 18 (11–26) years after the diagnosis. RV systolic dysfunction was found in 16.7% of CLS individuals using RV free-wall strain (RVFWS) compared to 2.2 to 4.4% with conventional measurements. RV systolic function measurements were lower in the CLS than in the control group: TAPSE (23.3 ± 4.0 vs. 25.2 ± 3.4, p = 0.004) and RVFWS (24.9 ± 4.6 vs. 26.8 ± 4.7, p = 0.032). Modifiable cardiovascular risk factors such as obesity (p = 0.022) and smoking (p = 0.028) were independently associated with reduced RVFWS. In conclusion, RV systolic function impairment was frequent in long-term survivors of childhood leukemia, underscoring the importance of RV assessment, including RVFWS, in the cardiac surveillance of these patients
In-hospital outcomes of mechanical complications in acute myocardial infarction: Analysis from a nationwide Spanish database
Background: Mechanical complications represent an important cause of mortality in myocardial infarction (MI) patients. This is a nationwide study performed to evaluate possible changes in epidemiology or prognosis of these complications with current available strategies.Methods: Information was obtained from the minimum basis data set of the Spanish National Health System, including all hospitalizations for acute myocardial infarction (AMI) from 2010 to 2015. Risk-standardized in-hospital mortality ratio was calculated using multilevel risk adjustment models.Results: A total of 241,760 AMI episodes were analyzed, MI mechanical complications were observed in 842 patients: cardiac tamponade in 587, ventricular septal rupture in 126, and mitral regurgitation due to papillary muscle or chordae tendineae rupture in 155 (there was more than one complication in 21 patients). In-hospital mortality was 59.5%. On multivariate adjustment, variables with significant impact on in-hospital mortality were: age (OR 1.06; 95% CI 1.04-1.07; p < 0.001), ST-segment elevation AMI (OR 2.91; 95% CI 1.88-4.5; p < 0.001), cardiogenic shock (OR 2.35; 95% CI 1.66-3.32; p < 0.001), cardio-respiratory failure (OR 3.48; 95% CI 2.37-5.09; p < 0.001), and chronic obstructive pulmonary disease (OR 1.85; 95% CI 1.07-3.20; p < 0.001). No significant trends in risk-adjusted in-hospital mortality were detected (IRR 0.997; p = 0.109). Cardiac intensive care unit availability and more experience with mechanical complications management were associated with lower adjusted mortality rates (56.7 ± 5.8 vs. 60.1 ± 4.5; and 57 ± 6.1 vs. 59.9 ± 5.6, respectively; p < 0.001).Conclusions: Mechanical complications occur in 3.5 per thousand AMI, with no significant trends to better survival over the past few years. Advanced age, cardiogenic shock and cardio-respiratory failure are the most important risk factors for in-hospital mortality. Higher experience and specialized cardiac intensive care units are associated with better outcomes
I Jornadas sobre Arte, Ecología y Uso Público de Espacios Naturales Protegidos
Publicación de las Jornadas que celebró el mes de marzo de 2016, en el Parque Nacional Las Tablas de Daimiel, la asociación Cultura de Ribera con el objetivo de hacer de la cultura y el arte elementos para la conservación de nuestros Espacios Naturales Protegidos.
Además de dar unas nociones sobre el paisaje y el territorio de La Mancha Húmeda, en la obra, se traza un panorama histórico sobre Las Tablas y su importancia como el primer Parque Nacional que fue declarado, en gran medida, gracias a la presión ciudadana y del, por entonces, incipiente movimiento ecologista. También se puede encontrar una visión ética de la conservación medioambiental, los antecedentes históricos y experiencias actuales del arte como vector para la conservación de los Espacios Naturales Protegidos y una reflexión sobre el papel del arte y las humanidades en el contexto de la crisis ecológica global. La obra se cierra con un artículo sobre la figura de Ignacio Meco, artista que en su obra aunaba arte y conservación del medio y que tuvo su casa taller en la Zona de Protección de Las Tablas
In-hospital outcomes of mechanical complications in acute myocardial infarction: Analysis from a nationwide Spanish database
Background: Mechanical complications represent an important cause of mortality in myocardial infarction (MI) patients. This is a nationwide study performed to evaluate possible changes in epidemiology or prognosis of these complications with current available strategies.Methods: Information was obtained from the minimum basis data set of the Spanish National Health System, including all hospitalizations for acute myocardial infarction (AMI) from 2010 to 2015. Risk-standardized in-hospital mortality ratio was calculated using multilevel risk adjustment models.Results: A total of 241,760 AMI episodes were analyzed, MI mechanical complications were observed in 842 patients: cardiac tamponade in 587, ventricular septal rupture in 126, and mitral regurgitation due to papillary muscle or chordae tendineae rupture in 155 (there was more than one complication in 21 patients). In-hospital mortality was 59.5%. On multivariate adjustment, variables with significant impact on in-hospital mortality were: age (OR 1.06; 95% CI 1.04–1.07; p < 0.001), ST-segment elevation AMI (OR 2.91; 95% CI 1.88–4.5; p < 0.001), cardiogenic shock (OR 2.35; 95% CI 1.66–3.32; p < 0.001), cardio-respiratory failure (OR 3.48; 95% CI 2.37–5.09; p < 0.001), and chronic obstructive pulmonary disease (OR 1.85; 95% CI 1.07–3.20; p < 0.001). No significant trends in risk-adjusted in-hospital mortality were detected (IRR 0.997; p = 0.109). Cardiac intensive care unit availability and more experience with mechanical complications management were associated with lower adjusted mortality rates (56.7 ± 5.8 vs. 60.1 ± 4.5; and 57 ± 6.1 vs. 59.9 ± 5.6, respectively; p < 0.001).Conclusions: Mechanical complications occur in 3.5 per thousand AMI, with no significant trends to better survival over the past few years. Advanced age, cardiogenic shock and cardio-respiratory failure are the most important risk factors for in-hospital mortality. Higher experience and specialized cardiac intensive care units are associated with better outcomes
Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics
[Abstract] Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on prognosis. The objective of the present study was to estimate the prevalence of hyperkalaemia in outpatients with HFrEF and its impact on achieving optimal medical treatment. For this purpose, a multicentre, prospective, and observational study was carried out on consecutive HFrEF patients who were monitored as outpatients in heart failure (HF) units and who, in the opinion of their doctor, received optimal medical treatment. A total of 565 HFrEF patients were included from 16 specialised HF units. The mean age was 66 ± 12 years, 78% were male, 45% had an ischemic cause, 39% had atrial fibrillation, 43% were diabetic, 42% had a glomerular filtration rate < 60 mL/min/1.7 m2, and the mean left ventricular ejection fraction was 31 ± 7%. Treatment at the study entry included: 76% on diuretics, 13% on ivabradine, 7% on digoxin, 18.9% on angiotensin-conversing enzyme inhibitors (ACEi), 11.3% on angiotensin receptors blockers (ARBs), 63.8% on angiotensin-neprilysin inhibitors (ARNi), 78.5% on mineralocorticoid receptor antagonists (MRAs), and 92.9% on beta-blockers. Potassium levels in the baseline analysis were: ≤5 mEq/L = 80.5%, 5.1–5.4 mEq/L = 13.8%, 5.5–5.9 mEq/L = 4.6%, and ≥6 mEq/L = 1.06%. Hyperkalaemia was the reason for not prescribing or reaching the target dose of an MRAs in 34.8% and 12.5% of patients, respectively. The impact of hyperkalaemia on not prescribing or dropping below the target dose in relation to ACEi, ARBs, and ARNi was significantly less. In conclusion, hyperkalaemia is a frequent problem in the management of patients with HFrEF and a limiting factor in the optimisation of medical treatment.AstraZeneca Farmacéutica; ESR-17-1324
Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).
There is a lack of evidence regarding the benefits of β-blocker treatment after invasively managed acute myocardial infarction (MI) without reduced left ventricular ejection fraction (LVEF).
The tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT) trial is a pragmatic, controlled, prospective, randomized, open-label blinded endpoint (PROBE design) clinical trial testing the benefits of β-blocker maintenance therapy in patients discharged after MI with or without ST-segment elevation. Patients eligible for participation are those managed invasively during index hospitalization (coronary angiography), with LVEF >40%, and no history of heart failure (HF). At discharge, patients will be randomized 1:1 to β-blocker therapy (agent and dose according to treating physician) or no β-blocker therapy. The primary endpoint is a composite of all-cause death, non-fatal reinfarction, or HF hospitalization over a median follow-up period of 2.75 years (minimum 2 years, maximum 3 years). Key secondary endpoints include the incidence of the individual components of the primary composite endpoint, the incidence of cardiac death, and incidence of malignant ventricular arrhythmias or resuscitated cardiac arrest. The primary endpoint will be analysed according to the intention-to-treat principle.
The REBOOT trial will provide robust evidence to guide the prescription of β-blockers to patients discharged after MI without reduced LVEF.REBOOT is a non-commercial trial whose main sponsor is the Spanish National Center for Cardiovascular
Research (CNIC). The study also received partial funding from the BI group through the CIBERCV network.S
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
Background: The aim of this study was to analyze the impact of the presence of heart failure (HF) on the clinical profile and outcomes in patients with atrial fibrillation (AF) anticoagulated with rivaroxaban.
Methods: Observational and non-interventional study that included AF adults recruited from 79 Spanish centers, anticoagulated with rivaroxaban ≥ 6 months before inclusion. Data were analyzed according to baseline HF status.
Results: Out of 1,433 patients, 326 (22.7%) had HF at baseline. Compared to patients without HF, HF patients were older (75.3 ± 9.9 vs. 73.8 ± 9.6 years; p = 0.01), had more diabetes (36.5% vs. 24.3%; p < 0.01), coronary artery disease (28.2% vs. 12.9%; p < 0.01), renal insufficiency (31.7% vs. 22.6%; p = 0.01), higher CHA2DS2-VASc (4.5 ± 1.6 vs. 3.2 ± 1.4; p < 0.01) and HAS-BLED (1.8 ± 1.1 vs. 1.5 ± 1.0; p < 0.01). After a median follow-up of 2.5 years, among HF patients, annual rates of stroke/systemic embolism/transient ischemic attack, MACE-non-fatal myocardial infarction, revascularization and cardiovascular death-, cardiovascular death, and major bleeding were 1.2%, 3.0%, 2.0%, and 1.4%, respectively. Compared to those patients without HF, HF patients had greater annual rates of MACE (3.0% vs. 0.5%; p < 0.01) and cardiovascular death (2.0% vs. 0.2%; p < 0.01), without significant differences regarding other outcomes, including thromboembolic or bleeding events. Previous HF was an independent predictor of MACE (odds ratio 3.4; 95% confidence interval 1.6-7.3; p = 0.002) but not for thromboembolic events or major bleeding.
Conclusions: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding
- …